Apellis Pharmaceuticals (United States)

Recent papers from Apellis Pharmaceuticals (United States)

1. C3 complement silencing prevents acetylcholine receptor loss and reduces complement activation in the rat passive transfer myasthenia gravis modelJournal of Translational Medicine · 2026
2. Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human studyThe Lancet · 2026
3. Aggressive retinopathy of prematurity: characteristics and risk factors for retreatmentBritish Journal of Ophthalmology · 2026
4. Early Versus Delayed Pegcetacoplan Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration in OAKS, DERBY, and GALEAmerican Journal of Ophthalmology · 2026
5. An Intracellular C3-CFB Complement Axis Reprograms Tubular Metabolism and Chromatin to Drive Kidney Fibrosis 2307504The Journal of Immunology · 2026
6. Expert Opinion: Management of Intraocular Inflammation and Vasculitis After Intravitreal Pegcetacoplan for Geographic AtrophyOphthalmic surgery, lasers & imaging retina · 2026
7. Predictive Value of Perilesional Fundus Autofluorescence Patterns and OCT-Based Ellipsoid Zone/Retinal Pigment Epithelium Loss Ratios in Geographic Atrophy Growth RatesOphthalmology Science · 2026
8. Macular telangiectasia masqueradersSurvey of Ophthalmology · 2026
9. ‘…completely exhausted and weak, really drained.’: a multinational qualitative interview study of healthcare provider, patient, and caregiver experiences of C3 glomerulopathy and primary (idiopathic) immune complex membranoproliferative glomerulonephritis diagnosis, burden and managementFrontiers in Nephrology · 2026
10. Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment ComparisonsAdvances in Therapy · 2026
11. Efficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label ExtensionClinical ophthalmology · 2026
12. Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis: Phase 3 VALIANT Subgroup AnalysisClinical Journal of the American Society of Nephrology · 2026
13. Multi-grader validation of the telemedicine retinopathy of prematurity severity scoreScientific Reports · 2026
14. From Classroom to Cleanroom: Building a Skilled Cell and Gene Therapy WorkforceCytotherapy · 2026
15. Pathologic evaluation of pig kidney and heart xenografts: 2024 recommendations from the Banff Xenotransplantation Pathology Working GroupAmerican Journal of Transplantation · 2026
16. Wcn26-9116 Efficacy of Pegcetacoplan in Patients With Lower Baseline Proteinuria: A Subgroup Analysis From the Valiant TrialKidney International Reports · 2026
17. Real-world clinical characteristics and treatment outcomes in PNH patients prescribed pegcetacoplan across europe, the United States and CanadaBlood · 2025
18. Low risk for meningococcal and other encapsulated bacteria infections with systemically administered pegcetacoplan in paroxysmal nocturnal hemoglobinuria and C3 glomerulopathiesBlood · 2025
19. Real-World Patient Characteristics, Burden, and Quality of Life in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative GlomerulonephritisKidney360 · 2025
20. Cell-autonomous complement C3 activity in prostate epithelial cells suppresses malignant transformation through tonic restrain of the MYC-tumorigenesis program 3135The Journal of Immunology · 2025